NMDA Enhancement Combined With Omega-3 for Early Dementia

Launched by CHANG GUNG MEMORIAL HOSPITAL · Dec 23, 2021

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a new treatment combining a drug called DAOIB with omega-3 fatty acids in people who have early stages of dementia, specifically those with mild cognitive impairment (aMCI) or mild Alzheimer’s disease (AD). The goal is to see if this combination can improve thinking skills, overall functioning, and quality of life compared to a placebo, which is a harmless substance that looks like the treatment but has no active ingredients. The trial will last for 24 weeks and will involve 140 participants, who will be randomly assigned to either the treatment group or the placebo group and monitored every eight weeks.

To be eligible for the trial, participants must have a clinical diagnosis of Alzheimer's disease or mild cognitive impairment and a certain score on a mental status test; specifically, their score should be between 10 and 26 on the MMSE test. They should also have a Clinical Dementia Rating (CDR) of 0.5 or 1. Some people will not be able to participate, including those with certain other serious health conditions or who have used specific medications recently. This trial is not yet recruiting participants, but it aims to help improve treatment options for early dementia in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Clinical diagnosis of Alzheimer's disease or mild cognitive impairment
• • MMSE between 10-26
• • CDR 1 or 0.5
• Exclusion Criteria:
• • Hachinski Ischemic Score \> 4
• • Substance abuse/dependence
• • Parkinson disease, epilepsy, dementia with psychotic features
• • Major depressive disorder
• • Major physical illnesses
• • memantine or special omega-3 fatty acids therapy within 3 months before enrollment
• • Severe visual or hearing impairment